drugset / Trial / NCT03177278

A Study to Assess the Metabolism, Excretion, and Mass Balance of Radio-Labeled Plazomicin

NCT03177278

Phase 1 Completed 6 enrolled Achaogen, Inc. Celerion · collab
NaSingle-groupOpen-labelTreatment

Summary

This is a single-center, open label, non-randomized metabolism, excretion, and mass balance study of a single IV infusion of \[14C\]-plazomicin in healthy, adult male subjects.

Timeline

Start
2017-06-16
Primary completion
2017-07-10
Completion
2017-07-10

Drugs

EvaluationDrugModalityDoseRoute
Subject plazomicin Small molecule Intravenous

Indications

No indication recorded.